Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
DyskinesiasParkinson DiseaseMovement DisordersParkinsonian Disorders
Interventions
DRUG

AFQ056

DRUG

Placebo

Trial Locations (28)

1085

Novartis Investigative Site, Budapest

7400

Novartis Investigative Site, Kaposvár

12163

Novartis Investigative Site, Berlin

14547

Novartis Investigative Site, Beelitz-Heilstätten

20014

Novartis Investigative Site, Donostia / San Sebastian

26655

Novartis Investigative Site, Westerstede/Oldenburg

28006

Novartis Investigative Site, Madrid

33604

Novartis Investigative Site, Pessac

34128

Novartis Investigative Site, Kassel

39100

Novartis Investigative Site, Bolzano

40225

Novartis Investigative Site, Düsseldorf

44791

Novartis Investigative Site, Bochum

56126

Novartis Investigative Site, Pisa

59037

Novartis Investigative Site, Lille

63003

Novartis Investigative Site, Clermont-Ferrand

80113

Novartis Investigative Site, Englewood

80804

Novartis Investigative Site, München

81675

Novartis Investigative Site, München

86021

Novartis Investigative Site, Poitiers

94089

Novartis Investigative Site, Sunnyvale

N6A 4G5

Novartis Investigative Site, London

J9J 0A5

Novartis Investigative Site, Gatineau

04103

Novartis Investigative Site, Leipzig

07646

Novartis Investigative Site, Stadtroda

H-6725

Novartis Investigative Site, Szeged

00163

Novartis Investigative Site, Roma

08190

Novartis Investigative Site, Sant Cugat del Vallès

08036

Novartis Investigative Site, Barcelona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY